Business
PDS: HPV16 Head and Neck Cancer announcement
PDS: HPV16 Head and Neck Cancer announcement.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \n \n \n Reach: 16 December 2022\n \n \n \n \n NetScientific plc\n \n \n \n (\"NetScientific\" or the \"Company\")\n \n \n \n PDS Biotech Completes First Stage of Enrolment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer\n \n \n \n \n VERSATILE-002 Phase 2 study investigates PDS0101 in combination with Merck's KEYTRUDA® (pembrolizumab) in both checkpoint inhibitor refractory and checkpoint inhibitor naïve patients\n \n \n \n NetScientific Plc (AIM: NSCI), investment and commercialisation group with an international portfolio of innovative life science, sustainability and technology companies, reports that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), has announced the completion of enrolment in the first stage of the checkpoint inhibitor refractory group of its VERSATILE-002 Phase 2 study for the potential treatment of recurrent and/or metastatic human papillomavirus (HPV16)-positive head and neck cancer. 90% of HPV-associated head and neck cancers in the US are reported to be caused by HPV16, as reported in a study published in the Journal of Clinical Medicine.\n \n \n VERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and safety of PDS0101 administered in combination with pembrolizumab (KEYTRUDA®) in adults with HPV16 and PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). VERSATILE-002 is investigating two patient populations of HPV16-positive head and neck cancer patients whose cancer has returned or spread. The first group has not been previously treated with a checkpoint inhibitor (CPI naïve). The second group of patients has failed treatments including checkpoint inhibitor therapy (CPI refractory). \n \n \n \n Dr Ilian Iliev, CEO of NetScientific, commented:\n \n \n \n \n \"We are delighted with PDS Biotech's continued progress in its clinical trials, including the Phase 2 trial for combined therapy with Merck's Keytruda® drug as detailed in their announcement. Congratulations to Frank and his team with their company's continued advancements\n \n \n .\"\n \n \n \n \n Dr Lauren V. Wood, Chief Medical Officer of PDS Biotech, said:\n \n \n \n \n \"We are very pleased to have completed enrolment among checkpoint inhibitor refractory patients in this first stage for this group...